Skip to main content
profile image
Selected Works of Walter J. Urba, MD, PhD
Contribution to Book
A Phase Ib Evaluation of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
Cancer therapy: monoclonal antibodies, Iymphokines: new developments in surgical oncology and chemo· and hormonal therapy (1989)
  • R. G. Steis, National Institutes of Health
  • J. Clark, National Institutes of Health
  • D. L. Longo, National Institutes of Health
  • J. Smith, National Institutes of Health
  • R. Miller, National Institutes of Health
  • F. Ruscetti, National Institutes of Health
  • J. Hursey, Memorial Hospital of South Bend
  • W. Urba, National Institutes of Health
Link
Abstract
Colony-stimulating factors (CSFs) are glycoproteins that were originally characterized as agents capable of enhancing myeloid stem cell growth and differentiation and mature myeloid cell function. With the availability of large quantities of these agents in recombinant form [1–4], it was soon demonstrated that they could as well increase the rate of myeloid cell proliferation in vivo and increase blood myeloid cell numbers [5–8]. The most obvious potential application of these agents in cancer therapy would be in the restoration of myeloid cell number and function in patients following myelosuppressive chemotherapy regimens [7, 8]. If effective in this regard, the CSFs might allow the administration of more dose-intense chemotherapy regimens, which might result in higher tumor response rates than those obtained at conventional doses. Because CSFs can also stimulate granulocyte and monocyte function [9–13], and such activated cells can specifically recognize and lyse tumor cells [14–17], another potential application of these agents might be as antitumor drugs which mediate their antitumor effects through activation of effector cell function. To evaluate the potential of CSFs in this regard, we conducted a phase lb study of recombinant human GM-CSF (rHuGM-CSF) in patients with a variety of malignancies. We evaluated not only the hematopoietic and toxic effects of this agent, but also its effects on granulocyte and monocyte function. This preliminary report summarizes our experience with rHuGM-CSF in doses of up to 50 mcg/kg.
Keywords
  • Peripheral Blood Count,
  • A375 Melanoma Cell,
  • Monocyte Function,
  • Peripheral White Blood Cell Count,
  • Peripheral Blood Granulocyte
Disciplines
Publication Date
1989
Editor
Hans G. Beger, Markus Büchler, Ralph A. Reisfeld, Gregor Schulz
Publisher
Springer-Verlag
ISBN
978-3-642-73723-7
DOI
10.1007/978-3-642-73721-3_13
Citation Information
R. G. Steis, J. Clark, D. L. Longo, J. Smith, et al.. "A Phase Ib Evaluation of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor" BerlinCancer therapy: monoclonal antibodies, Iymphokines: new developments in surgical oncology and chemo· and hormonal therapy (1989) p. 103 - 111
Available at: http://works.bepress.com/walter-urba/79/